Skip to main content

Drug companies are making an accounting change after the SEC cracked down on Biogen

Reporters and analysts covering first-quarter earnings from drug companies may have noticed a change in how they account for upfront payments made to finance research and development at companies in which they have acquired equity stakes.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.